Canada Markets close in 2 hrs 16 mins

TFF Pharmaceuticals, Inc. (0K3.F)

Frankfurt - Frankfurt Delayed Price. Currency in EUR
Add to watchlist
6.05+0.05 (+0.83%)
As of 09:16AM CET. Market open.
Full screen
Previous Close6.00
Bid5.60 x N/A
Ask5.80 x N/A
Day's Range6.05 - 6.05
52 Week Range6.00 - 16.60
Avg. Volume9
Market Cap153.499M
Beta (5Y Monthly)2.07
PE Ratio (TTM)N/A
EPS (TTM)-1.02
Earnings DateMar. 08, 2022 - Mar. 14, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est25.00
  • Simply Wall St.

    TFF Pharmaceuticals, Inc. (NASDAQ:TFFP): Are Analysts Optimistic?

    We feel now is a pretty good time to analyse TFF Pharmaceuticals, Inc.'s ( NASDAQ:TFFP ) business as it appears the...

  • GlobeNewswire

    TFF Pharmaceuticals Announces Final Data from Phase 1b Study of Inhaled Voriconazole Powder in Asthma Patients

    Final Safety and Pharmacokinetic Data Continue to Support Progression to Phase 2 in the Near Term for Treatment of Invasive Pulmonary Aspergillosis (IPA), Including Patients with Mild to Moderate Asthma Pharmacokinetic Data Revealed No Differences in Patients Using Bronchodilators Compared to Healthy Subjects; Allows for Inclusion of Broader Patient Populations in Upcoming Phase 2 Studies Company Expects to Generate Phase 2 Data in IPA in 2022; Data Suggest Potential Utility in Treating Allergic

  • GlobeNewswire

    TFF Pharmaceuticals Hosting Science Day on December 13, 2021

    AUSTIN, Texas, Dec. 06, 2021 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announced that it will host a science day related to two of the company’s lead assets, inhaled voriconazole for invasive pulmonary aspergillosis (IPA) and inhaled AUG-3387 for COVID-19, on Monday, December 13, 2021 from 1:30p